SAN DIEGO, Feb. 4, 2021 /PRNewswire/ -- Aethlon Medical,
Inc. (Nasdaq: AEMD), a medical device technology company focused on
unmet needs in global health, today announced that it will issue
financial results for its third quarter fiscal year 2021, ended
December 31, 2020, at 4:15 p.m. EST
on Wednesday, February 10, 2021.
Management will host a conference call on Wednesday, February 10, 2021 at 4:30 p.m. EST to review financial results and
recent corporate developments. Following management's formal
remarks, there will be a question and answer session.
Interested parties can register for the conference by navigating
to https://dpregister.com/sreg/10152271/e275c301d3. Please
note that registered participants will receive their dial in number
upon registration.
Interested parties without internet access or unable to
pre-register may dial in by calling:
PARTICIPANT DIAL IN
(TOLL FREE):
|
1-844-836-8741
|
PARTICIPANT
INTERNATIONAL DIAL IN:
|
1-412-317-5442
|
All callers should ask for the Aethlon Medical, Inc. conference
call.
A replay of the call will be available approximately one hour
after the end of the call through February
17, 2021. The replay can be accessed via Aethlon Medical's
website or by dialing 1-877-344-7529 (domestic) or 1-412-317-0088
(international) or Canada toll
free at 1-855-669-9658. The replay conference ID number is
10152271.
About Aethlon and the Hemopurifier®
Aethlon is focused on addressing unmet needs in global health.
The Aethlon Hemopurifier is a clinical-stage immunotherapeutic
device designed to combat cancer and life-threatening viral
infections. In cancer, the Hemopurifier is designed to deplete the
presence of circulating tumor-derived exosomes that promote immune
suppression.
The Hemopurifier® is an FDA designated "Breakthrough Device"
related to the treatment of individuals with advanced or metastatic
cancer who are either unresponsive to or intolerant of standard of
care therapy, and with cancer types in which exosomes have been
shown to participate in the development or severity of the disease.
Under an Investigational Device Exemption (IDE) application, in
October 2019, the FDA approved an
Early Feasibility Study (EFS), which is the device equivalent of a
Phase 1 clinical trial for a drug or biologic, in a single center,
open label trial in 10 to 12 subjects. The study is
evaluating the HEMOPURIFIER® for reducing cancer-associated
exosomes prior to the administration of standard-of-care
pembrolizumab (KEYTRUDA®), which is a first-line therapy for
patients with recurrent and/or metastatic squamous cell carcinoma
of the head and neck. The EFS is being conducted at the
University of Pittsburgh Medical Center
Hillman Cancer Center.
The Hemopurifier also holds a Breakthrough Device designation
related to life-threatening viruses that are not addressed with
approved therapies. In June
2020, the FDA approved an amendment to the Company's
existing open IDE for the Hemopurifier in life threatening viral
infections, to allow for the treatment of patients with
SARS-CoV-2/COVID-19 infection. This will allow for up to 40
of these patients to be treated under a new Early Feasibility Study
protocol at up to 20 clinical sites in the U.S.
Aethlon also owns 80% of Exosome Sciences, Inc., which is
focused on the discovery of exosomal biomarkers to diagnose and
monitor cancer and neurological disease progression. Additional
information can be found online
at www.AethlonMedical.com and www.ExosomeSciences.com.
Company Contact:
Jim
Frakes
Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com
Media Contact:
Tony Russo, Ph.D.
Russo Partners, LLC
tony.russo@russopartnersllc.com
212-845-4251
Investor Contact:
Susan
Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com
212-966-3650
View original
content:http://www.prnewswire.com/news-releases/aethlon-medical-to-release-third-quarter-financial-results-and-host-conference-call-on-february-10-2021-301222088.html
SOURCE Aethlon Medical, Inc.